CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
Authors
Keywords
Cancer immunotherapy, iNKT cells, CD1d, Tumor targeting, Fusion protein
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 62, Issue 4, Pages 747-760
Publisher
Springer Nature
Online
2012-12-14
DOI
10.1007/s00262-012-1381-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
- (2014) W.-S. Chang et al. JOURNAL OF IMMUNOLOGY
- Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells
- (2012) Q. Shao et al. BLOOD
- Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up
- (2012) Famke L. Schneiders et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of -GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells
- (2011) A. J. Nicol et al. CLINICAL CANCER RESEARCH
- Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges
- (2011) Madhav V. Dhodapkar et al. CLINICAL IMMUNOLOGY
- Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
- (2010) Kazuki Yamasaki et al. CLINICAL IMMUNOLOGY
- Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
- (2010) Leonid S. Metelitsa CLINICAL IMMUNOLOGY
- Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation
- (2010) T. Iyoda et al. INTERNATIONAL IMMUNOLOGY
- Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency
- (2010) G. Wingender et al. JOURNAL OF IMMUNOLOGY
- Combination therapy ofin vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma
- (2009) Naoki Kunii et al. CANCER SCIENCE
- Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms
- (2009) D. Bagnara et al. HAEMATOLOGICA
- Cutting Edge: B and T Lymphocyte Attenuator Signaling on NKT Cells Inhibits Cytokine Release and Tissue Injury in Early Immune Responses
- (2009) M. L. Miller et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: CD28 Engagement Releases Antigen-Activated Invariant NKT Cells from the Inhibitory Effects of PD-1
- (2009) J. Wang et al. JOURNAL OF IMMUNOLOGY
- PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
- (2009) V. V. Parekh et al. JOURNAL OF IMMUNOLOGY
- Enrichment of Human CD4+ V 24/V 11 Invariant NKT Cells in Intrahepatic Malignant Tumors
- (2009) G. Bricard et al. JOURNAL OF IMMUNOLOGY
- Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma
- (2008) G. J. Renukaradhya et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started